MedTrace Logo

Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities.

NCT05375097 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 162

Last updated 2022-07-01

No results posted yet for this study

Summary

This was a retrospective registry-based study utilizing data collected in association with clinical care of patients. All data was stored in electronic health records at Terveystalo data base, and no patients were contacted for the study.

Conditions

Interventions

OTHER

Erenumab

Patients who met the responder definition of two or more erenumab prescriptions with no evidence of switch to other CGRPi were included in the main analyses

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-03
Primary Completion
2021-05-14
Completion
2021-05-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05375097 on ClinicalTrials.gov